Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.98 USD | -2.33% | -6.34% | -22.60% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
MarketScreener Editorial Features
Temporary respite for the Nasdaq | January 19, 2022 at 10:05 am EST | |
ANALYST RECOMMENDATIONS : Activision Blizzard, Chevron, Exxon Mobil, Gilead, Goldman Sachs... | January 19, 2022 at 06:09 am EST |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- MarketScreener Editorial Features